Advanced search

Vol 54, No 6 (2020)
Review Article
Published online: 2020-09-17

open access

View PDF Download PDF file
Page views 7094
Article views/downloads 5070
Get Citation

Connect on Social Media

Connect on Social Media

Pediatric multiple sclerosis – current status of epidemiology, diagnosis and treatment

Waldemar Brola1, Barbara Steinborn2
DOI: 10.5603/PJNNS.a2020.0069
Pubmed: 32940341
Neurol Neurochir Pol 2020;54(6):508-517.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that mostly affects younger adults. However, the first symptoms of MS can appear in children and adolescents before the age of 18, and we call this paediatric MS (PMS). It is estimated that paediatric MS accounts for 3-5% of the general population of patients with MS. Despite the fundamental si-milarities to adult MS, PMS has many distinctive features. Paediatric MS has a milder course compared to adults, but leads to sig-nificant disability at an early age. PMS is relapsing-remitting in 95-98% of cases; the primary progressive manifestation is much less common than in adults. The differential diagnosis of MS in children should include other childhood demyelinating diseases, mitochondrial and metabolic diseases, connective tissue diseases, and neuroborreliosis. Differentiating acute disseminated en-cephalomyelitis (ADEM) from the first onset of MS remains the biggest challenge. Over the past 10 years, understanding of the epidemiology, pathophysiology, diagnosis, and treatment of MS in children has significantly expanded. The diagnostic criteria leading to earlier diagnosis and initiation of disease-modifying therapy (DMT) have changed, and the number of drugs used in children has increased. However, many important issues require further research. This review discusses the current state of knowledge regarding the epidemiology, diagnosis, and treatment of multiple sclerosis in children.

Keywords: multiple sclerosisdevelopment ageepidemiologydiagnosistreatment

Article available in PDF format

View PDF Download PDF file

References

  1. Fisher KS, Cuascut FX, Rivera VM, et al. Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines. 2020; 8(4).
    CrossRefPubMed
  2. Krysko KM, Graves JS, Rensel M, et al. US Network of Pediatric MS Centers. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020; 88(1): 42–55.
    CrossRefPubMed
  3. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018; 18(1): 27.
    CrossRefPubMed
  4. Renoux C, Vukusic S, Confavreux C, et al. Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007; 356(25): 2603–2613.
    CrossRefPubMed
  5. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013; 19(10): 1261–1267.
    CrossRefPubMed
  6. Rensel M. Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies. Children (Basel). 2019; 6(6).
    CrossRefPubMed
  7. Galardi MM, Gaudioso C, Ahmadi S, et al. Differential Diagnosis of Pediatric Multiple Sclerosis. Children (Basel). 2019; 6(6).
    CrossRefPubMed
  8. An Q, Fan CH, Xu SM. Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes. Eur Rev Med Pharmacol Sci. 2018; 22(17): 5747–5754.
    CrossRefPubMed
  9. Wong YuY, de Mol CL, van der Vuurst de Vries RM, et al. Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2): e528.
    CrossRefPubMed
  10. Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature. J Child Neurol. 2019; 34(12): 705–712.
    CrossRefPubMed
  11. Boiko A, Vorobeychik G, Paty D, et al. University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002; 59(7): 1006–1010.
    CrossRefPubMed
  12. Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012; 27(11): 1378–1383.
    CrossRefPubMed
  13. Gadoth N. Multiple sclerosis in children. Brain Dev. 2003; 25(4): 229–232.
    CrossRefPubMed
  14. Wang CX, Greenberg BM. Pediatric Multiple Sclerosis: From Recognition to Practical Clinical Management. Neurol Clin. 2018; 36(1): 135–149.
    CrossRefPubMed
  15. Huppke B, Ellenberger D, Rosewich H, et al. Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol. 2014; 21(3): 441–446.
    CrossRefPubMed
  16. Oksenberg JR, Baranzini SE, Sawcer S, et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008; 9(7): 516–526.
    CrossRefPubMed
  17. Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2004; 4(3): 245–252.
    CrossRefPubMed
  18. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol. 2009; 22(3): 219–225.
    CrossRefPubMed
  19. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011; 10(5): 436–445.
    CrossRefPubMed
  20. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010; 67(5): 618–624.
    CrossRefPubMed
  21. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000; 11(2): 220–224.
    CrossRefPubMed
  22. Hedström AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler. 2016; 22(8): 1021–1026.
    CrossRefPubMed
  23. Mikaeloff Y, Caridade G, Tardieu M, et al. KIDSEP study group. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain. 2007; 130(Pt 10): 2589–2595.
    CrossRefPubMed
  24. Rotstein DL, Cortese M, Fung TT, et al. Body size and risk of MS in two cohorts of US women. Neurology. 2009; 73(19): 1543–1550.
    CrossRefPubMed
  25. Langer-Gould A, Brara SM, Beaber BE, et al. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013; 80(6): 548–552.
    CrossRefPubMed
  26. McDonald J, Graves J, Waldman A, et al. A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 2016; 6: 87–92.
    CrossRefPubMed
  27. Montgomery S, Hiyoshi A, Burkill S, et al. Concussion in adolescence and risk of multiple sclerosis. Ann Neurol. 2017; 82(4): 554–561.
    CrossRefPubMed
  28. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002; 59(12): 1922–1928.
    CrossRefPubMed
  29. Mikaeloff Y, Suissa S, Vallée L, et al. KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004; 144(2): 246–252.
    CrossRefPubMed
  30. Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2007; 6(10): 887–902.
    CrossRefPubMed
  31. Ruggieri M, Iannetti P, Polizzi A, et al. Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004; 25 Suppl 4: S326–S335.
    CrossRefPubMed
  32. Yeh EA, Weinstock-Guttman B, Ramanathan M, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009; 132(Pt 12): 3392–3400.
    CrossRefPubMed
  33. McKay KA, Manouchehrinia A, Berrigan L, et al. Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. JAMA Neurol. 2019 [Epub ahead of print].
    CrossRefPubMed
  34. Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009; 66(1): 54–59.
    CrossRefPubMed
  35. Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014; 3(2): 186–193.
    CrossRefPubMed
  36. Ness JM, Chabas D, Sadovnick AD, et al. International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007; 68(16 Suppl 2): S37–S45.
    CrossRefPubMed
  37. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol. 2002; 51(4): 475–480.
    CrossRefPubMed
  38. Miller D, Leary S. Primary-progressive multiple sclerosis. The Lancet Neurology. 2007; 6(10): 903–912.
    CrossRef
  39. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121–127.
    CrossRefPubMed
  40. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6): 840–846.
    CrossRefPubMed
  41. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292–302.
    CrossRefPubMed
  42. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.
    CrossRefPubMed
  43. Krupp LB, et al. B Banwell Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68(16 ): S7–12.
    CrossRef
  44. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017; 89(3): 269–278.
    CrossRefPubMed
  45. Jurkiewicz E, Kotulska K. [Neuroimaging of multiple sclerosis in children]. Neurol Neurochir Pol. 2011; 45(2): 152–160.
    CrossRefPubMed
  46. Dębska J, Kotulska-Józwiak K, Pawliszak P, et al. Spinal cord lesions in children and adolescents with multiple sclerosis - Magnetic resonance imaging. Neurol Neurochir Pol. 2017; 51(1): 77–81.
    CrossRefPubMed
  47. Hahn JS, Pohl D, Rensel M, et al. International Pediatric MS Study Group. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology. 2007; 68(16 Suppl 2): S13–S22.
    CrossRefPubMed
  48. Tenembaum S, Chitnis T, Ness J, et al. International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology. 2007; 68(16 Suppl 2): S23–S36.
    CrossRefPubMed
  49. Alper G, Heyman R, Wang Li. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol. 2009; 51(6): 480–486.
    CrossRefPubMed
  50. Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123 Pt 12: 2407–2422.
    CrossRefPubMed
  51. Callen DJA, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009; 72(11): 968–973.
    CrossRefPubMed
  52. Ketelslegers IA, Neuteboom RF, Boon M, et al. Dutch Pediatric MS Study Group. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology. 2010; 74(18): 1412–1415.
    CrossRefPubMed
  53. O'Mahony J, Bar-Or A, Arnold DL, et al. Canadian Pediatric Demyelinating Disease Network. Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program. J Child Neurol. 2013; 28(2): 184–197.
    CrossRefPubMed
  54. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018; 15(1): 134–1399.
    CrossRefPubMed
  55. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019; 266(5): 1280–1286.
    CrossRefPubMed
  56. Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010; 16(10): 1258–1267.
    CrossRefPubMed
  57. Lattanzi S, Cagnetti C, Danni M, et al. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017; 264(8): 1697–1704.
    CrossRefPubMed
  58. Chitnis T, Ghezzi A, Bajer-Kornek B, et al. Pediatric multiple sclerosis: Escalation and emerging treatments. Neurology. 2016; 87(9 Suppl 2): S103–S109.
    CrossRefPubMed
  59. Chitnis T, Arnold DL, Banwell B, et al. PARADIGMS Study Group. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018; 379(11): 1017–1027.
    CrossRefPubMed
  60. Deiva K, Huppke P, Banwell B, et al. Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG. J Neurol Neurosurg Psychiatry. 2020; 91(1): 58–66.
    CrossRefPubMed
  61. Waubant E, Banwell B, Wassmer E, et al. IPMSSG. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology. 2019; 92(22): e2538–e2549.
    CrossRefPubMed
  62. https://clinicaltrials.gov.
  63. Ghezzi A, Amato MP, Makhani N, et al. Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology. 2016; 87(9 Suppl 2): S97–S9S102.
    CrossRefPubMed
  64. Narula S, Hopkins SE, Banwell B. Treatment of pediatric multiple sclerosis. Curr Treat Options Neurol. 2015; 17(3): 336.
    CrossRefPubMed
  65. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006; 66(4): 472–476.
    CrossRefPubMed
  66. Tenembaum SN, Banwell B, Pohl D, et al. REPLAY Study Group. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013; 28(7): 849–856.
    CrossRefPubMed
  67. Kornek B, Bernert G, Balassy C, et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003; 34(3): 120–126.
    CrossRefPubMed
  68. Alroughani R, Das R, Penner N, et al. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Pediatr Neurol. 2018; 83: 19–24.
    CrossRefPubMed
  69. Kornek B, Aboul-Enein F, Rostasy K, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013; 70(4): 469–475.
    CrossRefPubMed
  70. Ghezzi A, Pozzilli C, Grimaldi LME, et al. Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013; 19(8): 1106–1112.
    CrossRefPubMed
  71. Ghezzi A, Moiola L, Pozzilli C, et al. MS Study Group-Italian Society of Neurology. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174.
    CrossRefPubMed
  72. Alroughani R, Ahmed SF, Behbehani R, et al. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. Pediatr Neurol. 2017; 70: 56–60.
    CrossRefPubMed
  73. Arnal-Garcia C, García-Montero MaR, Málaga I, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013; 17(1): 50–54.
    CrossRefPubMed
  74. Salzer J, Lycke J, Wickström R, et al. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016; 263(2): 322–326.
    CrossRefPubMed
  75. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014; 51(1): 114–118.
    CrossRefPubMed
  76. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014; 83(2): 142–150.
    CrossRefPubMed
  77. Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009; 72(24): 2076–2082.
    CrossRefPubMed
  78. Gusev E, Boiko A, Bikova O, et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg. 2002; 104(3): 203–207.
    CrossRefPubMed
  79. Till C, Noguera A, Verhey LH, et al. Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. J Int Neuropsychol Soc. 2016; 22(10): 1050–1060.
    CrossRefPubMed
  80. Amato MP, Goretti B, Ghezzi A, et al. Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010; 75(13): 1134–1140.
    CrossRefPubMed
  81. Amato MP, Goretti B, Ghezzi A, et al. MS Study Group of the Italian Neurological Society. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014; 83(16): 1432–1438.
    CrossRefPubMed
  82. Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005; 64(5): 891–894.
    CrossRefPubMed
  83. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36(7): 980–988.
    CrossRefPubMed
  84. Cardoso M, Olmo NR, Fragoso YD. Systematic Review of Cognitive Dysfunction in Pediatric and Juvenile Multiple Sclerosis. Pediatr Neurol. 2015; 53(4): 287–292.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note